XML 39 R27.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segments of Business and Geographic Areas (Tables) | 9 Months Ended
--- | ---
Oct. 01, 2017
Segment Reporting [Abstract] |
Sales By Segment Of Business |
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 1,285 |  |  | 1,291 |  |  | (0.5 | )%
International |  | 2,071 |  |  | 1,970 |  |  | 5.1 |
Total |  | 3,356 |  |  | 3,261 |  |  | 2.9 |
Pharmaceutical |  |  |  |  |  |
United States |  | 5,816 |  |  | 5,042 |  |  | 15.4 |
International |  | 3,879 |  |  | 3,358 |  |  | 15.5 |
Total |  | 9,695 |  |  | 8,400 |  |  | 15.4 |
Medical Devices |  |  |  |  |  |
United States |  | 3,189 |  |  | 3,048 |  |  | 4.6 |
International |  | 3,410 |  |  | 3,111 |  |  | 9.6 |
Total |  | 6,599 |  |  | 6,159 |  |  | 7.1 |
Worldwide |  |  |  |  |  |
United States |  | 10,290 |  |  | 9,381 |  |  | 9.7 |
International |  | 9,360 |  |  | 8,439 |  |  | 10.9 |
Total |  | $ | 19,650 |  |  | 17,820 |  |  | 10.3 | %
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 4,186 |  |  | 4,033 |  |  | 3.8 | %
International |  | 5,876 |  |  | 5,842 |  |  | 0.6 |
Total |  | 10,062 |  |  | 9,875 |  |  | 1.9 |
Pharmaceutical |  |  |  |  |  |
United States |  | 15,698 |  |  | 15,123 |  |  | 3.8 |
International |  | 10,877 |  |  | 10,109 |  |  | 7.6 |
Total |  | 26,575 |  |  | 25,232 |  |  | 5.3 |
Medical Devices |  |  |  |  |  |
United States |  | 9,510 |  |  | 9,118 |  |  | 4.3 |
International |  | 10,108 |  |  | 9,559 |  |  | 5.7 |
Total |  | 19,618 |  |  | 18,677 |  |  | 5.0 |
Worldwide |  |  |  |  |  |
United States |  | 29,394 |  |  | 28,274 |  |  | 4.0 |
International |  | 26,861 |  |  | 25,510 |  |  | 5.3 |
Total |  | $ | 56,255 |  |  | 53,784 |  |  | 4.6 | %
Operating Profit by Segment of Business |
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
Consumer(1) |  | $ | 878 |  |  | 679 |  |  | 29.3 | %
Pharmaceutical(2) |  | 2,857 |  |  | 3,309 |  |  | (13.7 | )
Medical Devices(3) |  | 1,383 |  |  | 1,526 |  |  | (9.4 | )
Segments operating profit |  | 5,118 |  |  | 5,514 |  |  | (7.2 | )
Less: Expense not allocated to segments (4) |  | 328 |  |  | 233 |  |  |
Worldwide income before tax |  | $ | 4,790 |  |  | 5,281 |  |  | (9.3 | )%
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
Consumer(1) |  | $ | 2,132 |  |  | 1,816 |  |  | 17.4 | %
Pharmaceutical(2) |  | 9,934 |  |  | 10,340 |  |  | (3.9 | )
Medical Devices(3) |  | 3,938 |  |  | 4,041 |  |  | (2.5 | )
Segments operating profit |  | 16,004 |  |  | 16,197 |  |  | (1.2 | )
Less: Expense not allocated to segments (4) |  | 891 |  |  | 718 |  |  |
Worldwide income before taxes |  | $ | 15,113 |  |  | 15,479 |  |  | (2.4 | )%
(1) Includes a gain of $0.4 billion from the divestiture of COMPEED® (2) Includes a positive adjustment of $0.5 billion to previous reserve estimates in the fiscal nine months of 2016. Includes acquisition costs related to the Actelion acquisition of $0.4 billion and $0.6 billion in the fiscal third quarter and fiscal nine months of 2017, respectively. Includes a gain of $0.2 billion related to monetization of future royalty receivables in the fiscal nine months of 2017. Includes a gain of $0.3 billion and $0.2 billion in the fiscal nine months of 2017 and 2016, respectively, related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (3) Includes a restructuring related charge of $0.2 billion and $0.1 billion in the fiscal third quarters of 2017 and 2016, respectively. Includes a restructuring related charge of $0.5 billion and $0.4 billion in the fiscal nine months of 2017 and 2016, respectively. Includes litigation expense of $0.1 billion and $0.1 billion in the fiscal third quarter of 2017 and 2016, respectively. Includes litigation expense of $0.5 billion and $0.7 billion in the fiscal nine months of 2017 and 2016, respectively. Includes an asset impairment of $0.2 billion primarily related to the insulin pump business in the fiscal nine months of 2017. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas |
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
United States |  | $ | 10,290 |  |  | 9,381 |  |  | 9.7 | %
Europe |  | 4,308 |  |  | 3,832 |  |  | 12.4 |
Western Hemisphere, excluding U.S. |  | 1,569 |  |  | 1,396 |  |  | 12.4 |
Asia-Pacific, Africa |  | 3,483 |  |  | 3,211 |  |  | 8.5 |
Total |  | $ | 19,650 |  |  | 17,820 |  |  | 10.3 | %
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | October 1, 2017 |  | October 2, 2016 |  | Percent Change
United States |  | $ | 29,394 |  |  | 28,274 |  |  | 4.0 | %
Europe |  | 12,398 |  |  | 11,769 |  |  | 5.3 |
Western Hemisphere, excluding U.S. |  | 4,522 |  |  | 4,269 |  |  | 5.9 |
Asia-Pacific, Africa |  | 9,941 |  |  | 9,472 |  |  | 5.0 |
Total |  | $ | 56,255 |  |  | 53,784 |  |  | 4.6 | %

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration